title: Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
abstract: Recombinant interferon alpha-C is a new strain of the alpha interferon family. It was given to 33 patients with measurable metastatic renal cell carcinoma of whom 31 were evaluable. Protocol consisted of 3 million U/d for 2 weeks, then 3 million U/m2 every other day until progression. No complete response was observed. Three patients (9.7%) had partial response for a mean duration of 5.6 months and eight patients (25.8%) were stabilized for a mean of 4.3 months. Responsive sites were mainly lung, bone, and kidney, while side effects were generally mild. better results were observed in previously nephrectomized patients who had not received chemotherapy or hormonotherapy for recurrent or metastatic disease (p less than 0.05), and also in patients with a brief disease-free interval and short delay from presenting symptoms of the primary tumor until interferon treatment (p less than 0.05). Median survival was significantly longer in responders than in progressors (p less than 0.05). We suggest that the efficacy of recombinant interferon alpha-C in a low-dose regime versus other types of interferon as first-line therapy for inoperable, metastatic, or locally recurrent renal cell carcinoma should be investigated in a prospective, controlled, randomized study.
authors.affiliation: Department of Oncology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Merimsky
authors.forename: M
authors.initials: M
authors.lastname: Inbar
authors.forename: E
authors.initials: E
authors.lastname: Merimsky
authors.forename: F
authors.initials: F
authors.lastname: Kovner
authors.forename: E
authors.initials: E
authors.lastname: Spitzer
authors.forename: R
authors.initials: R
authors.lastname: Laufer
authors.forename: Z
authors.initials: Z
authors.lastname: Braf
authors.forename: S
authors.initials: S
authors.lastname: Chaitchik
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D002493:Central Nervous System Diseases / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins